These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 21235516)
1. Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). Liao QH; Gao QZ; Wei J; Chou KC Med Chem; 2011 Jan; 7(1):24-31. PubMed ID: 21235516 [TBL] [Abstract][Full Text] [Related]
2. Docking and molecular dynamics study on the inhibitory activity of N, N-disubstituted-trifluoro-3-amino-2-propanols-based inhibitors of cholesteryl ester transfer protein. Dong BL; Liao QH; Wei J J Mol Model; 2011 Jul; 17(7):1727-34. PubMed ID: 21057835 [TBL] [Abstract][Full Text] [Related]
3. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors. Al-Anazi M; Al-Najjar BO; Khairuddean M Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058 [TBL] [Abstract][Full Text] [Related]
4. Structural elucidation of unique inhibitory activities of two thiazolo[ 4,5-d]pyrimidines against epidermal growth factor receptor (EGFR): implications for successful drug design. Mitrasinovic PM Med Chem; 2014; 10(1):46-58. PubMed ID: 23628079 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
7. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer. Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903 [TBL] [Abstract][Full Text] [Related]
8. How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFR E J; Liu Y; Guan S; Luo Z; Han F; Han W; Wang S; Zhang H Molecules; 2020 Feb; 25(4):. PubMed ID: 32085409 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor. Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165 [TBL] [Abstract][Full Text] [Related]
11. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis. Sudha A; Srinivasan P; Rameshthangam P J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory activity against epidermal growth factor receptor (EGFR) based on single point mutations of active site residues. Mitrasinovic PM Med Chem; 2014 May; 10(3):252-70. PubMed ID: 23628078 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity. Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427 [TBL] [Abstract][Full Text] [Related]
14. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. Engel J; Smith S; Lategahn J; Tumbrink HL; Goebel L; Becker C; Hennes E; Keul M; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Hengstler JG; Rauh D J Med Chem; 2017 Sep; 60(18):7725-7744. PubMed ID: 28853575 [TBL] [Abstract][Full Text] [Related]
15. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2. Sangande F; Julianti E; Tjahjono DH Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664 [TBL] [Abstract][Full Text] [Related]
16. Identification of potent EGFR inhibitors from TCM Database@Taiwan. Yang SC; Chang SS; Chen HY; Chen CY PLoS Comput Biol; 2011 Oct; 7(10):e1002189. PubMed ID: 22022246 [TBL] [Abstract][Full Text] [Related]
17. Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953 [TBL] [Abstract][Full Text] [Related]
18. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
19. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy. Budipramana K; Sangande F Chem Biol Drug Des; 2024 May; 103(5):e14534. PubMed ID: 38697951 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and preclinical evaluation of 5-methyl-N Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]